HK1215025A1 - 純化的吡咯並喹啉基-吡咯烷-2,5-二酮組合物和用於製備且使用其的方法 - Google Patents

純化的吡咯並喹啉基-吡咯烷-2,5-二酮組合物和用於製備且使用其的方法 Download PDF

Info

Publication number
HK1215025A1
HK1215025A1 HK16103027.3A HK16103027A HK1215025A1 HK 1215025 A1 HK1215025 A1 HK 1215025A1 HK 16103027 A HK16103027 A HK 16103027A HK 1215025 A1 HK1215025 A1 HK 1215025A1
Authority
HK
Hong Kong
Prior art keywords
dione
pyrrolidine
dihydro
quinolin
pyrrolo
Prior art date
Application number
HK16103027.3A
Other languages
English (en)
Chinese (zh)
Inventor
P. Reed David
R. Barnes Neil
C. Kane John
A. Lee Christopher
Chen Jian-Xie
P. Redmon Martin
Original Assignee
Arqule, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule, Inc. filed Critical Arqule, Inc.
Publication of HK1215025A1 publication Critical patent/HK1215025A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK16103027.3A 2009-12-23 2016-03-16 純化的吡咯並喹啉基-吡咯烷-2,5-二酮組合物和用於製備且使用其的方法 HK1215025A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28956309P 2009-12-23 2009-12-23
US61/289563 2009-12-23

Publications (1)

Publication Number Publication Date
HK1215025A1 true HK1215025A1 (zh) 2016-08-12

Family

ID=44188284

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103027.3A HK1215025A1 (zh) 2009-12-23 2016-03-16 純化的吡咯並喹啉基-吡咯烷-2,5-二酮組合物和用於製備且使用其的方法

Country Status (19)

Country Link
US (3) US8552192B2 (cg-RX-API-DMAC10.html)
EP (2) EP2515904A4 (cg-RX-API-DMAC10.html)
JP (2) JP2013515737A (cg-RX-API-DMAC10.html)
KR (2) KR101669707B1 (cg-RX-API-DMAC10.html)
CN (2) CN104910159A (cg-RX-API-DMAC10.html)
AU (2) AU2010336533B9 (cg-RX-API-DMAC10.html)
BR (1) BR112012015656A2 (cg-RX-API-DMAC10.html)
CA (1) CA2785503A1 (cg-RX-API-DMAC10.html)
CO (1) CO6561823A2 (cg-RX-API-DMAC10.html)
HK (1) HK1215025A1 (cg-RX-API-DMAC10.html)
MX (1) MX2012007259A (cg-RX-API-DMAC10.html)
MY (2) MY169232A (cg-RX-API-DMAC10.html)
NZ (2) NZ600800A (cg-RX-API-DMAC10.html)
PH (2) PH12012501293A1 (cg-RX-API-DMAC10.html)
RU (1) RU2556205C2 (cg-RX-API-DMAC10.html)
SG (1) SG181927A1 (cg-RX-API-DMAC10.html)
TW (3) TWI557125B (cg-RX-API-DMAC10.html)
WO (1) WO2011079142A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201204759B (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51826B (sr) * 2005-02-09 2012-02-29 Arqule Inc. Maleimid derivati, farmaceutske kompozicije i postupak lečenja kancera
JP2013515737A (ja) * 2009-12-23 2013-05-09 アークル インコーポレイテッド 精製されたピロロキノリニル−ピロリジン−2,5−ジオン組成物ならびにその調製方法および使用方法
KR20140146036A (ko) * 2011-07-07 2014-12-24 아르퀼 인코포레이티드 피롤로퀴놀리닐-피롤리딘-2,5-디온 제제 및 이의 제조 및 사용 방법
EP2841069A4 (en) * 2012-04-23 2015-09-02 Arqule Inc HIGHLY PYRROLOCHINOLINYL-PYRROL-2,5-DION AND PYRROLOCHINOLINYL-PYRROLIDIN-2,5-DION AND METHOD FOR THE PRODUCTION THEREOF
EP3021849B1 (en) * 2013-07-16 2019-10-09 Dr. Reddy's Laboratories Ltd. Novel crystalline forms of pemetrexed tromethamine salts
KR20250070131A (ko) * 2017-08-11 2025-05-20 액투에이트 테라퓨틱스 인크. 3-(5-플루오로벤조푸란-3-일)-4-(5-메틸-5H-[1,3]디옥솔로[4,5-f]인돌-7-일)피롤-2,5-디온의고체 형태
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4319740A4 (en) * 2021-04-07 2025-03-19 Crystalys Therapeutics, Inc. URAT1 INHIBITOR, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE4128015A1 (de) * 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
US5760237A (en) * 1995-08-25 1998-06-02 California Institute Of Technology Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary
WO2001044247A2 (en) * 1999-12-16 2001-06-21 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
ATE315017T1 (de) * 2002-07-31 2006-02-15 Firmenich & Cie Verfahren zur racematspaltung einer sclareolid- vorstufe
EP1786772A1 (en) * 2004-09-10 2007-05-23 Wyeth a Corporation of the State of Delaware Process for the scalable synthesis of 1, 3, 4, 9-tetrahydropyranoý3, 4-b¨-indole derivatives
RS51826B (sr) * 2005-02-09 2012-02-29 Arqule Inc. Maleimid derivati, farmaceutske kompozicije i postupak lečenja kancera
US20070185346A1 (en) * 2006-02-03 2007-08-09 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
CA2690799C (en) 2007-06-22 2015-06-16 Arqule, Inc. Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
CA2690782C (en) * 2007-06-22 2016-02-02 Arqule, Inc. Compositions and methods for treatment of cancer
JP2013515737A (ja) * 2009-12-23 2013-05-09 アークル インコーポレイテッド 精製されたピロロキノリニル−ピロリジン−2,5−ジオン組成物ならびにその調製方法および使用方法
EP2841069A4 (en) * 2012-04-23 2015-09-02 Arqule Inc HIGHLY PYRROLOCHINOLINYL-PYRROL-2,5-DION AND PYRROLOCHINOLINYL-PYRROLIDIN-2,5-DION AND METHOD FOR THE PRODUCTION THEREOF

Also Published As

Publication number Publication date
PH12012501293A1 (en) 2013-01-07
AU2015243015B2 (en) 2017-02-02
KR20160121602A (ko) 2016-10-19
AU2010336533B9 (en) 2015-10-08
CN104910159A (zh) 2015-09-16
RU2556205C2 (ru) 2015-07-10
KR101669707B1 (ko) 2016-10-27
NZ628087A (en) 2016-02-26
KR20120113760A (ko) 2012-10-15
AU2010336533A1 (en) 2012-07-12
WO2011079142A3 (en) 2011-11-24
WO2011079142A2 (en) 2011-06-30
NZ600800A (en) 2014-10-31
US8871933B2 (en) 2014-10-28
EP2515904A4 (en) 2013-07-03
CA2785503A1 (en) 2011-06-30
RU2012131344A (ru) 2014-01-27
CN102834097B (zh) 2015-06-17
US20160024076A1 (en) 2016-01-28
JP2013515737A (ja) 2013-05-09
AU2015243015A1 (en) 2015-11-05
ZA201204759B (en) 2014-03-26
US20110160242A1 (en) 2011-06-30
TW201141865A (en) 2011-12-01
US20140031551A1 (en) 2014-01-30
TWI557125B (zh) 2016-11-11
CO6561823A2 (es) 2012-11-15
MY169232A (en) 2019-03-19
TW201542546A (zh) 2015-11-16
CN102834097A (zh) 2012-12-19
PH12014500310A1 (en) 2015-09-28
US8552192B2 (en) 2013-10-08
EP2515904A2 (en) 2012-10-31
AU2010336533B2 (en) 2015-09-10
EP3081567A3 (en) 2016-11-16
SG181927A1 (en) 2012-07-30
US9499540B2 (en) 2016-11-22
MY156701A (en) 2016-03-15
EP3081567A2 (en) 2016-10-19
TW201643163A (zh) 2016-12-16
MX2012007259A (es) 2015-05-15
TWI506026B (zh) 2015-11-01
BR112012015656A2 (pt) 2016-05-10
JP2016041712A (ja) 2016-03-31

Similar Documents

Publication Publication Date Title
CN102834097B (zh) 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法
US9597341B2 (en) Phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
CN109689641B (zh) 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法
JP2019521980A (ja) Jak阻害剤としてのピロロピリミジン化合物の結晶
TR201807101T4 (tr) İmidazo[4,5-c]kinolin-2-on bileşikler ve kanserin tedavi edilmesinde kullanımları.
EP4353724A1 (en) Compound as cdk kinase inhibitor and use thereof
KR20180073682A (ko) 피리미딘 유도체 및 그의 사용
CN116490188B (zh) 含氮杂环类衍生物的盐、晶型及其制备方法和应用
JP2021504332A (ja) ピラゾロピリジノン化合物
US8343977B2 (en) Substituted triazolo-pyrimidine compounds
US12384795B2 (en) Pyrimido[5,4-b]pyrrolizin compound, optical isomer thereof, preparation method therefor and use thereof
US12595246B2 (en) Crystalline and amorphous forms of N-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
HK1210471A1 (en) Novel pyrrolopyrimidine compounds as inhibitors of protein kinases